Linda S. Stewart, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 1 Hospital Rd, Oak Bluffs, MA 02557 Phone: 508-684-4500 Fax: 508-684-4502 |
Daniel E Pesch, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: One Hospital Road, Oak Bluffs, MA 02557 Phone: 508-693-0410 Fax: 508-696-8474 |
News Archive
The MRSA 'superbug' evades many of the measures introduced to combat its spread by infecting a common single-celled organism found almost everywhere in hospital wards, according to new research published in the journal Environmental Microbiology.
A court in China's Shandong province on Friday upheld a four-year, three-month prison sentence for human rights advocate Chen Guangcheng - who was arrested in China after attempting to bring a class-action lawsuit against the government for alleged human rights abuses associated with the enforcement of the country's one-child-per-family policy - the Washington Post reports.
Leveraging a $20,000 "Feeding Our Future" grant from the Sodexo Foundation, St. Anthony Central Hospital, along with volunteers from Sodexo and the Food Bank of the Rockies, serves 12,400 summer lunches to Denver children at risk of hunger. Sodexo's Feeding Our Future program provides school children who rely on free and reduced-price meals during the academic year with nutritious lunches during the summer break.
MagnaChip Semiconductor Corporation ("MagnaChip"), a Korean semiconductor company with a broad portfolio of analog and mixed-signal products and technologies, today announced a full range of "MXsensor" intelligent sensor product families featuring 0.18 micron mixed signal & analog technology with low power consumption.
VIVUS, Inc. today announced that additional data on Qnexa(TM), an investigational drug candidate for obesity, was presented at the 27th annual scientific meeting of The Obesity Society (TOS) in Washington D.C. Wesley W. Day, PhD, vice president of clinical development at VIVUS, presented the additional data from the company's two year-long phase 3 obesity trials during the Pharmacotherapy Update portion of the pre-conference on October 24, 2009.
› Verified 8 days ago